產(chǎn)品詳情
簡單介紹：
重組人血管內(nèi)皮生長因子165蛋白與其它公司提供的重組蛋白不同，rHuVEGF165蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人血管內(nèi)皮生長因子165蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測、ELISA等試驗(yàn)中.
詳情介紹：
重組人血管內(nèi)皮生長因子165蛋白
| Synonyms | Vascular Endothelial Growth Factor Isoform 165 |
| Species | Human |
| Accession | P15692 |
| GeneID | 7422 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人血管內(nèi)皮生長因子165蛋白Approximately 38.6 kDa, a disulfide-linked homodimeric protein consisting of two 166 amino acid polypeptide chains with Met at N-terminus. |
| Quantity | 2μg/10μg/1000μg |
| AA Sequence | 重組人血管內(nèi)皮生長因子165蛋白MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng/ml. |
| Physical Appearance | 重組人血管內(nèi)皮生長因子165蛋白Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuVEGF165 as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人血管內(nèi)皮生長因子165蛋白 | |
| Reference |
1. Leung DW, Cachianes G, Kuang WJ, et al. 1989. Science. 246:1306-9. 2. Byrne AM, Bouchier-Hayes DJ, Harmey JH. 2005. J Cell Mol Med. 9:777-94. 3. Robinson CJ, Stringer SE. 2001. J Cell Sci. 114:853-65. |
| Background | Vascular Endothelial Growth Factor is a sub-family of growth factors produced by cells, which stimulates vasculogenesis and angiogenesis. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (a.a.) in length. VEGF production can be induced in cells that are not receiving enough oxygen. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. Recombinant human VEGF165 contains 165 amino acids residues and it is a disulfide-linked homodimer. In addition, it shares 88 % a.a. with corresponding regions of mouse and rat, 96 % with porcine, 95 % with canine, and 93 % with feline, equine and bovine VEGF, respectively |
